RecruitingPhase 1psilocybin
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Sponsored by Portland VA Research Foundation, Inc
NCT ID
NCT04982796
Target Enrollment
30 participants
Start Date
2022-07-07
Est. Completion
2026-04-30
About This Study
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
Conditions Studied
Interventions
- •Psilocybin
- •Treatment-as-usual
Eligibility
Age:25 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * United States military Veteran * Moderate to severe methamphetamine use disorder using the DSM-V diagnostic criteria * Desire to cease or reduce methamphetamine use Exclusion Criteria: * Have uncontrolled hypertension or clinically significant cardiovascular disease * History of seizure disorder in adulthood * CNS metastases or symptomatic central nervous system (CNS) infection * Poorly controlled diabetes mellitus * Taking certain medications that may interact with psilocybin * History of any primary persistent psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, major depressive disorder with psychosis, or schizophreniform disorder * History of bipolar I disorder * Current eating disorder with active purging * History of hallucinogen use disorder * Pregnant or breast feeding
Study Locations (1)
Portland VA Health Care System
Vancouver, Washington, United States